[Clinical evaluation of norfloxacin in children].
We administered norfloxacin (NFLX) to 16 children aged 3 to 14 year-old at the dose of 5.2 to 17.2 mg/kg/day. We evaluated the efficacy and safety of NFLX in 6 children with respiratory tract infections, 8 urinary tract infections, and 2 gastrointestinal tract infections. Efficacy rate of NFLX was 93.8% and eradicated rate was 92.9%. Any adverse effects were not observed. These results suggested that NFLX could be used safely to the children.
Ihara
T
T
Department of Pediatrics, Mie University.
Kawaguchi
H
H
Ito
M
M
Kamiya
H
H
Sakurai
M
M
D000293:Adolescent; D000367:Age Factors; D001419:Bacteria / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D004751:Enteritis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D009643:Norfloxacin / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D009643:Norfloxacin